After listening to the commentary alongside the slides, the suggestion is that the funding is in place after the recent debenture and additional shares sold.

I had been under the impression that all of that money was mostly spoken for with other concerns.

An overall very disapointing presentation. Happy to be proven wrong, because there was plenty of suggestions of "very soon!" "exciting!" "developments in the works!" "MONEY in the wings!".  If any of those things come true, your shares will be worth more than .87 Canadian.

Apabetalone, which by all accounts is a remarkable therapeutic, continues to be handicapped by a company called Resverlogix.